Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations

Nucleic Acids Research

Volumn 36, Issue 16, 2008, Pages

  Coldwell, Kate E ^a   Cutts, Suzanne M ^a   Ognibene, Ted J ^b   Henderson, Paul T ^b   Phillips, Don R ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DOXORUBICIN; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN DNA; DOXORUBICIN-DNA;

ACCELERATOR MASS SPECTROMETRY; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DNA ADDUCT; DRUG DNA BINDING; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; CHEMISTRY; EVALUATION; INSTRUMENTATION; MAGNETIC AND ELECTROMAGNETIC EQUIPMENT; METHODOLOGY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DNA ADDUCTS; DOXORUBICIN; HUMANS; MASS SPECTROMETRY; PARTICLE ACCELERATORS;

EID: 52649163984     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkn439     Document Type: Article

References (70)

1. DeVita,V.T., Hellman,S. and Rosenberg,S.A. (eds). (2005) Cancer: principles and practice of oncology, 7th edn. Lippincott-Raven, Philadelphia.
2. Weiss,R.B. (1992) The Anthracyclines: Will we ever find a better doxorubicin? Semin. Oncol., 19, 670-685.
3. Minotti,G., Menna,P., Salvatorelli,E., Cairo,G. and Gianni,L. (2004) Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 56, 185-229.
4. Gewirtz,D.A. (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol., 57, 727-741.
5. Tewey,K.M., Rowe,T.C., Yang,L., Halligan,B.D. and Liu,L.F. (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science, 226, 466-468.
6. Gigli,M., Doglia,S.M., Millot,J.M., Valentini,L. and Manfait,M. (1988) Quantitative study of doxorubicin in living cell nuclei by microspectrofluorometry. Biochim. Biophys. Acta., 950, 13-20.
7. Cummings,J. and McArdle,C.S. (1986) Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug. Br. J. Cancer., 53, 835-838.
8. Terasaki,T., Iga,T., Sugiyama,Y., Sawada,Y. and Hanano,M. (1984) Nuclear binding as a determinant of tissue distribution of adriamycin, daunomycin, adriamycinol, daunorubicinol and actinomycin D. J. Pharmacobiodyn., 7, 269-277.
9. Sinha,B.K. and Chignell,C.F. (1979) Binding mode of chemically activated semiquinone free radicals from quinone anticancer agents to DNA. Chem. Biol. Interact., 28, 301-308.
10. Cutts,S.M., Nudelman,A., Rephaeli,A. and Phillips,D.R. (2005) The power and potential of doxorubicin-DNA adducts. IUBMB Life, 57, 73-81.
11. Cutts,S.M., Swift,L.P., Rephaeli,A., Nudelman,A. and Phillips,D.R. (2005) Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde. Curr. Med. Chem. Anti-Cancer Agents 5, 431-447.
12. Zeman,S.M., Phillips,D.R. and Crothers,D.M. (1998) Characterization of covalent Adriamycin-DNA adducts. Proc. Natl Acad. Sci. USA, 95 11561-1565.
13. Taatjes,D.J., Gaudiano,G., Resing,K. and Koch,T.H. (1996) Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J. Med. Chem., 39, 4135-138.
14. Wang,A.H., Gao,Y.G., Liaw,Y.C. and Li,Y.K. (1991) Formaldehyde cross-links daunorubicin and DNA efficiently: HPLC and X-ray diffraction studies. Biochemistry, 30, 3812-3815.
15. Konopa,J. (1983) Adriamycin and daunomycin induce interstrand DNA crosslinks in Hela S3 Cells. Biochem. Biophys. Res. Commun., 110, 819-826.
16. Cutts,S.M., Rephaeli,A., Nudelman,A., Hmelnitsky,I. and Phillips,D.R. (2001) Molecular basis for the synergistic interaction of Adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res., 61, 8194-8202.
17. Cullinane,C., Cutts,S.M., Panousis,C. and Phillips,D.R. (2000) Interstrand cross-linking by adriamycin in nuclear and mitochondrial DNA of MCF-7 cells. Nucleic Acids Res., 28, 1019-1025.
18. Cullinane,C., van Rosmalen,A. and Phillips,D.R. (1994) Does adriamycin induce interstrand cross-links in DNA? Biochemistry, 33, 4632-4638.
19. Cummings,J., Willmott,N., Hoey,B.M., Marley,E.S. and Smyth,J.F. (1992) The consequences of doxorubicin quinone reduction in vivo in tumour tissue. Biochem. Pharmacol., 44, 2165-2174.
20. Cullinane,C. and Phillips,D.R. (1990) Induction of stable transcriptional blockage sites by adriamycin: GpC specificity of apparent adriamycin-DNA adducts and dependence on iron(III) ions. Biochemistry, 29, 5638-5646.
21. Wallace,K.B. and Johnson,J.A. (1987) Oxygen-dependent effect of microsomes on the binding of doxorubicin to rat hepatic nuclear DNA. Mol. Pharmacol., 31, 307-311.
22. Taatjes,D.J., Fenick,D.J. and Koch,T.H. (1999) Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines. Chem. Res. Toxicol., 12, 588-596.
23. Cutts,S.M. and Phillips,D.R. (1995) Use of oligonucleotides to define the site of interstrand cross-links induced by Adriamycin. Nucleic Acids Res., 23, 2450-2456.
24. van Rosmalen,A., Cullinane,C., Cutts,S.M. and Phillips,D.R. (1995) Stability of adriamycin-induced DNA adducts and interstrand crosslinks. Nucleic Acids Res., 23, 42-50.
25. Cutts,S.M., Nudelman,A., Pillay,V., Spencer,D.M.S., Levovich,I., Rephaeli,A. and Phillips,D.R. (2005) Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance. Oncol. Res., 15, 199-213.
26. Vogel,J.S. (2005) Accelerator mass spectrometry for quantitative in vivo tracing. Biotechniques, Jun, Suppl, 25-29.
27. 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal. Bioanal. Chem., 378, 356-364.
28. H in biological samples using Accelerator mass spectrometry: Application in low-dose, dual-Isotope tracer studies in conjunction with 14C accelerator mass spectrometry. Chem. Res. Toxicol., 11, 1217-1222.
29. Buchholz,B.A., Pawley,N.H., Vogel,J.S. and Mauthe,R.J. (1997) Pyrethroid decrease in central nervous system from nerve agent pretreatment. J. Appl. Toxicol., 17, 231-234.
30. 14C]-benzene in B6C3F1 mice. Carcinogenesis, 18, 2421-2427.
31. Turteltaub,K.W. and Vogel,J.S. (2000) Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research. Curr. Pharm. Des., 6, 991-1007.
32. Poirier,M.C., Santella,R.M. and Weston,A. (2000) Carcinogen macromolecular adducts and their measurement. Carcinogenesis, 21, 353-359.
33. 14C]-labeled therapeutic dose. Cancer Res., 67, 6995-7002.
34. Hah,S.S., Sumbad,R.A., de Vere White,R.W., Turteltaub,K.W. and Henderson,P.T. (2007) Characterization of Oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations. Chem. Res. Toxicol., 20, 1745-1751.
35. Hah,S.S., Stivers,K.M., de Vere White,R.W. and Henderson,P.T. (2006) Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry. Chem. Res. Toxicol., 19, 622-626.
36. Hah,S.S., Mundt,J.M., Kim,H.M., Sumbad,R.A., Turteltaub,K.W. and Henderson,P.T. (2007) Measurement of 7,8-dihydro-8-oxo-2'-deoxyguanosine metabolism in MCF-7 cells at low concentrations using accelerator mass spectrometry. Proc. Natl Acad. Sci. USA, 104, 11203-11208.
37. Mundt,J., Hah,S., Sumbad,R., Schramm,V. and Henderson,P. (2008) Incorporation of extracellular 8-oxodG into DNA and RNA requires purine nucleoside phosphorylase in MCF-7 cells. Nucleic Acids Res., 36 228-236.
38. Cullinane,C., Cutts,S.M., van Rosmalen,A. and Phillips,D.R. (1994) Formation of adriamycin-DNA adducts in vitro. Nucleic Acids Res., 22, 2296-2303.
39. Soule,H.D., Vazguez,J., Long,A., Albert,S. and Brennan,M. (1973) A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst., 51, 1409-1416.
40. Calcabrini,A., Meschini,S., Stringaro,A., Cianfriglia,M., Arancia,G. and Molinari,A. (2000) Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells. Histochem. J., 32, 599-606.
41. Dingley,K.H., Ubick,E.A., Vogel,J.S. and Haack,K.W. (2005) DNA isolation and sample preparation for quantification of adduct levels by accelerator mass spectrometry. Methods Mol. Biol., 291, 21-27.
42. 14C bio-AMS preparation laboratory. Nucl. Instrum. Methods Phys. Res. B., 172, 404-408.
43. Brown,K., Dingley,K.H. and Turteltaub,K.W. (2005) Accelerator mass spectrometry for biomedical research. Meth. Enzymol., 402, 423-443.
44. Swift,L.P., Rephaeli,A., Nudelman,A., Phillips,D.R. and Cutts,S.M. (2006) Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res., 66, 4863-4871.
45. Cutts,S.M., Panousis,C., Masta,A. and Phillips,D.R. (1997) An oligonucleotide crosslinking assay for the analysis of individual drug-binding sites. Meth. Mol. Biol., 90, 107-115.
46. Taatjes,D.J., Gaudiano,G. and Koch,T.H. (1997) Production of formaldehyde and DNA-adriamycin or DNA-daunomycin adducts, initiated through redox chemistry of dithiothreitol/iron, xanthine oxidase/NADH/ iron, or glutathione/iron. Chem. Res. Toxicol., 10, 953-961.
47. Rizzo,V., Sacchi,N. and Menozzi,M. (1989) Kinetic studies of anthracycline-DNA interaction by stopped-flow confirm a complex association mechanism. Biochemistry, 28, 274-282.
48. DeGregorio,M.W., Dingley,K.H., Wurz,G.T., Ubick,E. and Turteltaub,K.W. (2006) Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations. Cancer Chemother. Pharmacol., 57, 335-342.
49. Ognibene,T.J., Bench,G., Brown,T.A., Peaslee,G.F. and Vogel,J.S. (2002) A new accelerator mass spectrometry system for C-14-quantification of biochemical samples. Internat. J. Mass Spectrom., 218, 255-264.
50. Swift,L.P. (2004) Enhancing the anticancer activity of Adriamycin Ph.D. Thesis. La Trobe University.
51. Harris,L.N., Yang,L., Liotcheva,V., Pauli,S., Iglehart,J.D., Colvin,O.M. and Hsieh,T.S. (2001) Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin. Cancer Res., 7, 1497-1504.
52. Binaschi,M., Capranico,G., Dal Bo,L. and Zunino,F. (1997) Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity. Mol. Pharmacol., 51, 1053-1059.
53. Capranico,G., Riva,A., Tinelli,S., Dasdia,T. and Zunino,F. (1987) Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei. Cancer Res., 47, 3752-3756.
54. Yamazaki,K., Isobe,H., Hanada,T., Betsuyaku,T., Hasegawa,A., Hizawa,N., Ogura,S. and Kawakami,Y. (1997) Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. Cancer Chemother. Pharmacol., 39, 192-198.
55. Scherf,U., Ross,D.T., Waltham,M., Smith,L.H., Lee,J.K., Tanabe,L., Kohn,K.W., Reinhold,W.C., Myers,T.G., Andrews,D.T. et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat. Genet., 24, 236-244.
56. Pinkel,D. (2000) Cancer cells, chemotherapy and gene clusters. Nat. Genet., 24, 208-209.
57. Mansilla,S., Pina,B. and Portugal,J. (2003) Daunorubicin-induced variations in gene transcription: Commitment to proliferation arrest, senescence and apoptosis. Biochem. J., 372, 703-711.
58. Kudoh,K., Ramanna,M., Ravatn,R., Elkahloun,A.G., Bittner,M.L., Meltzer,P.S., Trent,J.M., Dalton,W.S. and Chin,K.V. (2000) Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res., 60, 4161-4166.
59. Bagchi,D., Bagchi,M., Hassoun,E.A., Kelly,J. and Stohs,S.J. (1995) Adriamycin-induced hepatic and myocardial lipid peroxidation and DNA damage, and enhanced excretion of urinary lipid metabolites in rats. Toxicology, 95, 1-9.
60. Pierscinski,G., Drzewoski,J. and Nowak,D. (1994) The influence of doxorubicin and 4'-epi-doxorubicin on lipid peroxidation in mouse heart, lungs and liver. Part II. Pol. J. Pharmacol., 46, 55-59.
61. Ebeler,S.E., Clifford,A.J. and Shibamoto,T. (1997) Quantitative analysis by gas chromatography of volatile carbonyl compounds in expired air from mice and human. J. Chromatogr. B. Biomed. Sci. App., 702, 211-215.
62. Myers,C.E., Gianni,L., Simone,C.B., Klecker,R. and Greene,R. (1982) Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry, 21, 1707-1712.
63. Kato,S., Burke,P.J., Fenick,D.J., Taatjes,D.J., Bierbaum,V.M. and Koch,T.H. (2000) Mass spectrometric measurement of formaldehyde generated in breast cancer cells upon treatment with anthracycline antitumor drugs. Chem. Res. Toxicol., 13, 509-516.
64. Ebeler,S.E., Hinrichs,S.H., Clifford,A.J. and Shibamoto,T. (1994) Volatile carbonyl levels in tissues of transgenic mice with nerve sheath tumors. J. Chromatogr. B. Biomed. Sci. App., 654, 9-18.
65. Spanel,P., Smith,D., Holland,T.A., Al Singary,W. and Elder,J.B. (1999) Analysis of formaldehyde in the headspace of urine from bladder and prostate cancer patients using selected ion flow tube mass spectrometry. Rapid Common. Mass Spectrom., 13, 1354-1359.
66. Cummings,J., Bartoszek,A. and Smyth,J.F. (1991) Determination of covalent binding to intact DNA, RNA, and oligonucleotides by intercalating anticancer drugs using high-performance liquid chromatography. Studies with doxorubicin and NADPH cytochrome P-450 reductase. Anal. Biochem., 194, 146-155.
67. Skladanowski,A. and Konopa,J. (1994) Interstrand DNA cross-linking induced by anthracyclines in tumour cells. Biochem. Pharmacol., 47, 2269-2278.
68. Sharples,R.A., Cullinane,C. and Phillips,D.R. (2000) Adriamycin-induced inhibition of mitochondrial-encoded polypeptides as a model system for the identification of hotspots for DNA-damaging agents. Anticancer Drug Des., 15, 183-190.
69. 14C]-adriamycin to cellular macromolecules in vivo. Biochem. Pharmacol., 29, 1867-1868.
70. Swift,L.P., Cutts,S.M., Rephaeli,A., Nudelman,A. and Phillips,D.R. (2003) Activation of Adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine. Mol. Cancer Ther., 2, 189-198.